Mehrdad Arjomandi, MD

Professor
M_MED-VAMC-PULM
+1 415 221-4810 ext. 24393

Dr. Arjomandi grew up in Ahvaz, a small city in Southwestern Iran, and moved to the United States in 1986 in the aftermath of Iranian revolution (1979), Iraq's invasion of Iran (1980-88), and his family displacement inside Iran (1980-83). When in California, he began his higher education at Los Angeles Pierce College before transferring to University of California San Diego in 1988, where he obtained a bachelor degree in molecular biology and completed a senior honors thesis in developmental biology in Dr. Richard Firtel’s lab. He then attended Stanford University School of Medicine in 1991, completing two predoctoral research fellowships in Dr. Etienne Emile Beaulieu’s lab at INSERM in Paris, France, and Dr. John Cooke’s vascular biology lab at Stanford. Dr. Arjomandi then completed a residency in internal medicine at UCLA (1996-99) and a fellowship in pulmonary and critical care at UCSF (2000-03). He completed three additional years of research fellowship funded by the American Lung Association and Chest Foundation before successfully competing for an NIH K23 award in 2006 and then joining the pulmonary and critical care faculty at UCSF and San Francisco General Hospital (SFGH). In 2008, he obtained a joint appointment at the San Francisco VA Health Care System (SFVA).

Currently, Dr. Arjomandi is Professor of Medicine in the Divisions of Pulmonary, Critical Care, Allergy, and Sleep Medicine and Occupational, Environmental, and Climate Medicine at UCSF with a joint appointment at SFVA. He is Director of the UCSF Human Exposure Laboratory, Director of Environmental Medicine Clinic at SFVA, Director for the SF VA Airborne Hazard Exposure Study Center of Excellence, an investigator at the UCSF Center for Tobacco Control Research and Education, and a member of the UCSF Helen Diller Family Comprehensive Cancer Center.

Research Interests

The lung is constantly exposed to various environmental pollutants, allergens, and toxins, which interact with airways and alveoli and result in inflammation, injury, and disease. My laboratory primary research interest has been centered on the paradigm that respiratory exposures to pollutants and toxicants contribute to development and progression of chronic lung diseases, and may further yield systemic effects well beyond lungs. Under this paradigm, my research activities have focused on understanding the physiologic and biologic mechanisms via which environmental exposures contribute to chronic lung diseases and how knowledge of these mechanisms could be translated to ways to better define, prognosticate, and manage disease burden at both individual and societal levels.

I have dedicated my efforts to (1) investigate airway biology using inhalational exposure to ozone in humans as a model of lung injury simulating exacerbation in chronic lung disease, and (2) characterize the early cardiopulmonary changes due to exposure to tobacco smoke and the pathophysiology and biology associated with those changes.

Publications

The Effect of Chronic Altitude Exposure on COPD Outcomes in the SPIROMICS Cohort.

American journal of respiratory and critical care medicine

Suri R, Markovic D, Woo H, Arjomandi M, Barr RG, Bowler RP, Criner G, Curtis JL, Dransfield MT, Drummond MB, Fortis S, Han MK, Hoffman EA, Kaner RJ, Kaufman JD, Krishnan JA, Martinez FJ, Ohar J, Ortega VE, Paine Iii R, Soler X, Woodruff PG, Hansel NN, Cooper CB, Tashkin DP, Buhr RG, Barjaktarevic IZ

Response.

Chest

Seedahmed MI, Albirair MT, Whooley MA, Koth LL, Blanc PD, Arjomandi M

Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry.

JAMA

McKleroy W, Shing T, Anderson WH, Arjomandi M, Awan HA, Barjaktarevic I, Barr RG, Bleecker ER, Boscardin J, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Curtis JL, Dransfield M, Doerschuk CM, Dolezal BA, Drummond MB, Han MK, Hansel NN, Helton K, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Martinez FJ, Ohar J, Ortega VE, Paine R, Peters SP, Reinhardt JM, Rennard S, Smith BM, Tashkin DP, Couper D, Cooper CB, Woodruff PG

Changes in Lung Volumes with Spirometric Disease Progression in COPD.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Arjomandi M, Zeng S, Chen J, Bhatt SP, Abtin F, Barjaktarevic I, Barr RG, Bleecker ER, Buhr RG, Criner GJ, Comellas AP, Couper DJ, Curtis JL, Dransfield MT, Fortis S, Han MK, Hansel NN, Hoffman EA, Hokanson JE, Kaner RJ, Kanner RE, Krishnan JA, Labaki W, Lynch DA, Ortega VE, Peters SP, Woodruff PG, Cooper CB, Bowler RP, Paine R, Rennard SI, Tashkin DP, and the COPDGene and SPIROMICS Investigators

A MUC5B Gene Polymorphism, rs35705950-T Confers Protective Effects Against COVID-19 Hospitalization but not Severe Disease or Mortality.

American journal of respiratory and critical care medicine

Verma A, Minnier J, Wan ES, Huffman JE, Gao L, Joseph J, Ho YL, Wu WC, Cho K, Gorman BR, Rajeevan N, Pyarajan S, Garcon H, Meigs JB, Sun YV, Reaven PD, McGeary JE, Suzuki A, Gelernter J, Lynch JA, Peterson JM, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Gatsby E, Lynch KE, Bonomo RA, Freiberg M, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Huang RD, Polimanti R, Chang KM, Liao KP, Tsao PS, Wilson PWF, Hung A, O'Donnell CJ, Gaziano JM, Hauger RL, Iyengar SK, Luoh SW, Million Veteran Program COVID-19 Science Initiative

Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.

Chest

Fortis S, Quibrera PM, Comellas AP, Bhat SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, Barr RG, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB, Subpopulations and Intermediate Outcome Measures in COPD Study Investigators

Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.

The New England journal of medicine

Han MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, Brown SA, Buhr RG, Comellas AP, Cooper CB, Criner GJ, Dransfield MT, Drescher F, Folz RJ, Hansel NN, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Maddipati V, Martinez FJ, Mathews A, Meldrum C, McEvoy C, Nyunoya T, Rogers L, Stringer WW, Wendt CH, Wise RA, Wisniewski SR, Sciurba FC, Woodruff PG, RETHINC Study Group

Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage COPD.

American journal of respiratory and critical care medicine

Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, Barr RG, Comellas AP, Couper D, Cooper CB, Freeman C, Han M, Kaner RJ, Labaki W, Martinez FJ, Ortega VE, Peters SP, Paine R, Woodruff P, Curtis JL, Huffnagle GB, Stringer KA, Bowler RP, Esther CR, Reisdorph N, Huang YJ, SPIROMICS Research Group

Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait.

JAMA internal medicine

Verma A, Huffman JE, Gao L, Minnier J, Wu WC, Cho K, Ho YL, Gorman BR, Pyarajan S, Rajeevan N, Garcon H, Joseph J, McGeary JE, Suzuki A, Reaven PD, Wan ES, Lynch JA, Petersen JM, Meigs JB, Freiberg MS, Gatsby E, Lynch KE, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Bonomo RA, Thompson TK, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Gelernter J, Huang RDL, Polimanti R, Chang KM, Liao KP, Tsao PS, Sun YV, Wilson PWF, O'Donnell CJ, Hung AM, Gaziano JM, Hauger RL, Iyengar SK, Luoh SW, VA Million Veteran Program COVID-19 Science Initiative

Ratio of Forced Expiratory Volume in 1 second /Slow Vital Capacity (FEV1/SVC)<0.7 is associated with clinical, functional, and radiologic features of obstructive lung disease in smokers with preserved lung function.

Chest

Fortis S, Comellas A, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M, Hoesterey D, Buhr RG, Barr RG, Dolezal B, Ortega VE, Drummond MB, Arjomandi M, Kaner RJ, Kim V, Curtis JL, Bowler RP, Martinez F, Labaki WW, Cooper CB, O'Neal WK, Criner G, Hansel NN, Krishnan JA, Woodruff P, Couper D, Tashkin D, Barjaktarevic I

Military Burn Pits.

American journal of respiratory and critical care medicine

Sotolongo A, Falvo M, Santos S, Johnson I, Arjomandi M, Hines S, Krefft S, Osterholzer J

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.

International journal of chronic obstructive pulmonary disease

Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine Iii R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB